Sanofi will replace its CEO Paul Hudson, who has been in the position since September 2019.[2] Paul Hudson previously led Novartis Pharmaceuticals from 2016 to 2019.[2] Sanofi integrates artificial intelligence into its processes, where it supports decision-making in research and development, supply chain and drug manufacturing.[2] Using machine learning and data integration, they discovered 10 completely new drug targets in one year.[2] The AI agent evaluates at the development commissions whether the drug will advance to the next stage of trials.[2] In the Czech Republic and Slovakia, Paul-François Cossa replaced Emmanuelle Valentin as executive manager.[1] Conservatives in the US oppose the lowest national price (MFN) drug pricing model. The article summarizes these and other pharmaceutical news from the Pharmalittle newsletter.